Daiichi Sankyo is dedicated to bringing innovative therapies to as many patients as possible, and as quickly as possible. Its approach builds on more than 40 years of experience in oncology and a ...

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

The Contrast Media Market is projected to grow at a CAGR of 5-6%. Key factors influencing the contrast media market include ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

Fierce Pharma Asia RemeGen Otsuka Daiichi Sankyo Vor Biopharma Harbour BioMed AstraZeneca Autoimmune Diseases Licensing deals Datroway antibody-drug conjugates EGFR-mutated lung cancer GLP-1 Type ...

View the latest Daiichi Sankyo Co. Ltd. (DSKYF) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Europe has a way of making even the simplest train ride feel like something out of a storybook. With rail lines that stretch across mountains, slip through valleys, and hug coastlines, it’s easy ...

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu in March 2019 and Datroway in July 2020, except in Japan where Daiichi Sankyo maintains ...

AstraZeneca and Daiichi Sankyo have earned their second FDA approval for Datroway, scoring a nod for the drug to treat EGFR-mutated non-small cell lung cancer.

The FDA has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with NSCLC.

(Reuters) -AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the ...